Call for proposals
Innovative Medicines Initiative 2 – 10th Call for proposals – H2020-JTI-IMI2-2016-10-TWO-STAGE
Objectives and description
Innovative
Medicines Initiatives - IMI is a partnership between the EU and the
European pharmaceutical industry, represented by the European Federation
of Pharmaceutical Industries and Associations (EFPIA).
The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking has been created following the principles below:
· Research
related to the future of medicine should be undertaken in areas where
societal, public health and biomedical industry competitiveness goals
are aligned and require the pooling of resources and greater
collaboration between the public and private sectors, with the
involvement of small and medium-sized enterprises (SMEs);
· The scope of the initiative should be expanded to all areas of life science research and innovation;
· The
areas should be of public health interest, as identified by the World
Health Organisation (WHO) report on priority medicines for Europe and
the World.
In
this framework, it has been published the 10th Call for Proposals under
the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2).
The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop
next generation vaccines, medicines and treatments, such as new
antibiotics. It will build on the successes and lessons learnt under
IMI. Like IMI, it will bring together companies, universities, public
laboratories, innovative small and medium-sized enterprises (SMEs),
patient groups and regulators in collaborative projects that will pave
the way for breakthrough vaccines, medicines and treatments to tackle
Europe’s growing health challenges, and secure the future international
competitiveness of Europe’s pharmaceutical industry.
The 10th Call for Proposals for IMI 2 refers to the following topics:
The
overarching objective of this call topic is to reduce the risk and
burden of hypoglycaemia and, as a consequence, ultimately improve
glycaemic control in people with diabetes.
This
call topic aims to address the scarcity of epidemiologic, clinical,
genomic/biomarker, economic, patient reported outcome, and humanistic
data on the treatment path of prostate cancer including all stages of
the disease; leverage real-life data on patients from different European
countries, using existing registries, trial data, and data from
prostate cancer specialized centres as well as data from patient groups.
The
goal of this Topic is to make advances in three pain areas in a
complementary manner. These three Subtopics, each of which addresses a
specific scientific challenge, together offer significant opportunities
for cross-fertilisation:
Subtopic 3A: using Patient Reported Outcome Measures to improve the management of acute and chronic pain (PROMs);
Subtopic 3B:
improving the translatability of pharmacodynamic biomarkers in pain
pathways of healthy subjects and preclinical species (BIOM);
Subtopic 3C: improving translation in chronic pelvic pain (CPP).
The
overall vision of this topic is to create a large collaborative
paediatric network that facilitates the development and availability of
new drugs and other therapies, and the expansion of knowledge about
drugs currently in practice for the entire paediatric population.
The
overall objective is to develop/determine the best high throughput or
novel analytical and/or feedback control methods/tests to be used for
the parameters that need to be measured during manufacturing of
biopharmaceuticals, in particular the cell culture.
This
topic aims to unlock the therapeutic potential within the SLC gene
family by overcoming many of the technical barriers that have hindered
their study and prevented their exploitation as drug targets by
generating research tools and by making them freely available to the
scientific community.
This
project represents an opportunity to enable patients to better provide
their perspectives - in qualitative and quantitative terms - in the
medicines pathways from discovery to outcomes monitoring and beyond.
This
project offers a unique opportunity to create a European-wide research
strategy in collaboration and in alignment with US-based efforts that
overcome key bottlenecks in the development and testing of treatments
for ASD. It will build the necessary capacity, within Europe, for the
conduct of future trials, while also contributing towards a more unified
approach to research in ASD within Europe in the clinical sciences.
Eligible participants - Minimum conditions
The topics refer to Research and Innovation Actions, thus the eligible partners are: at least three legal entities established in a different Member State or associated country. All three legal entities shall be independent of each other.
The following participants are eligible for funding under the IMI 2:
· Independent
legal entities established in a Member State or an Associated Country,
or created under Union law and which fall within one of the following
categories:
1. micro, small and medium-sized enterprises and other companies with an annual turnover of EUR 500 million or less;
2. secondary and higher education establishments;
3. non-profit
organisations, including those carrying out research or technological
development as one of their main objectives or those that are patient
organisations;
· the Joint Research Centre;
· international European interest organisations
EU funding may be granted to international organisations and legal entity established in a third country provided that at least one of the following conditions is fulfilled:
a) the participation is deemed essential for carrying out the IMI2 JU action;
b) such
funding is provided for under a bilateral scientific and technological
agreement or any other arrangement between the Union and the
international organisation or, for entities established in third
countries, the country in which the legal entity is established.
Funding conditions and duration
The overall indicative budget for this call for proposals is 348.030.000 EUR, covered by the IMI2 JU and the EFPIA companies.
The indicative duration of each action is from 30 to 72 months, depending on the topic.
Deadline of proposals' submission
The deadline for the submission of proposals Stage 1 is on 28 March 2017 17:00:00 Brussels time, while the deadline for the Stage 2 is on 14 September 2017, 17:00:00 Brussels time.
Please note that entering and submitting short proposals for this Call can only be done through the electronic submission system of the Horizon 2020 Participant Portal.
Further information
Please find attached the call documentation.
IMI Partner Search Tool: http://www.imi.europa.eu/content/partner-search
IMI rules and procedures WEBINAR - 13 January 2017, 14:00 Central European Time (Brussels time) Registration open at https://attendee.gotowebinar.com/register/3200342277397832706
More information: http://www.imi.europa.eu/content/imi-2-call-10 and/or http://tinyurl.com/gstadfo
Kind regards,
Rosemary STREVINIOTI
Head of Brussels Office
European Office of Cyprus
Rue du Luxembourg 3, 2nd floor
B-1000 Brussels
Tel./Fax: +32 (0) 2 280 22 85
E-mail: strevinioti.rozamaria@ucy.ac.cy
PLEASE NOTE THAT THE GREEK TRANSLATION OF THE CALLS IS PROVIDED AT REQUEST OF ANY INTERESTED MEMBER (based on the decision of 22.12.2016 of the EOC Administrative Council).
|